Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-CRCP antibody [EPR9670(B)] (ab139264)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR9670(B)] to CRCP
  • Suitable for: WB, IHC-P, ICC/IF, IP
  • Reacts with: Mouse, Rat, Human

Overview

  • Product name

    Anti-CRCP antibody [EPR9670(B)]
    See all CRCP primary antibodies

  • Description

    Rabbit monoclonal [EPR9670(B)] to CRCP

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    ICC/IF
    Human
    IHC-P
    Human
    IP
    Human
    WB
    Mouse
    Rat
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide within Human CRCP aa 1-100 (N terminal). The exact sequence is proprietary.
    Database link: O75575

  • Positive control

    • WB: HeLa and Jurkat whole cell lysate (ab7899). Human prostate and ovary cancer tissue lysates. Mouse kidney and rat brain tissue lysates. IHC-P: Human ovarian carcinoma and breast tissues. ICC/IF: LnCap and HeLa cells. IP: Human prostate cancer tissue lysate.

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Properties

Images

  • Western blot - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Western blot - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    All lanes : Anti-CRCP antibody [EPR9670(B)] (ab139264) at 1/5000 dilution (unpurified)

    Lane 1 : Jurkat cell lysate
    Lane 2 : Mouse kidney tissue lysate
    Lane 3 : Rat brain tissue lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

    Predicted band size: 14 kDa
    Observed band size: 20 kDa
    why is the actual band size different from the predicted?



    Blocking buffer and concentration: 5% NFDM/TBST.

    Diluting buffer and concentration: 5% NFDM/TBST.

  • Western blot - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Western blot - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    All lanes : Anti-CRCP antibody [EPR9670(B)] (ab139264) at 1/10000 dilution (purified)

    Lane 1 : Jurkat cell lysate
    Lane 2 : Mouse kidney tissue lysate
    Lane 3 : Rat brain tissue lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

    Predicted band size: 14 kDa
    Observed band size: 20 kDa why is the actual band size different from the predicted?



    Blocking buffer and concentration: 5% NFDM/TBST.

    Diluting buffer and concentration: 5% NFDM/TBST.

  • Western blot - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Western blot - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    All lanes : Anti-CRCP antibody [EPR9670(B)] (ab139264) at 1/1000 dilution (unpurified)

    Lane 1 : Human ovary cancer lysate
    Lane 2 : HeLa lysate
    Lane 3 : Jurkat lysate
    Lane 4 : Human prostate cancer lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution

    Predicted band size: 14 kDa

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CRCP antibody [EPR9670(B)] (ab139264)

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human breast tissue labelling CRCP with unpurified ab139264 at 1/100. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Counterstained with Hematoxylin.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CRCP antibody [EPR9670(B)] (ab139264)

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human breast tissue labelling CRCP with purified ab139264 at 1/200. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Counterstained with Hematoxylin.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CRCP antibody [EPR9670(B)] (ab139264)

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human breast tissue labelling CRCP with unpurified ab139264 at 1/50.

    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CRCP antibody [EPR9670(B)] (ab139264)

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human ovarian carcinoma tissue labelling CRCP with unpurified ab139264 at 1/50.

    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • Immunocytochemistry/ Immunofluorescence - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Immunocytochemistry/ Immunofluorescence - Anti-CRCP antibody [EPR9670(B)] (ab139264)

    Immunocytochemsitry/Immunofluorescence analysis of LnCap cells labelling CRCP (red) with unpurified ab139264 at 1/100. Cells were fixed with 4% paraformaldehyde. An Alexa Fluor® 555-conjugated goat anti-rabbit IgG (1/200) was used as the secondary antibody. Counterstained with DAPI (blue).

  • Immunocytochemistry/ Immunofluorescence - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Immunocytochemistry/ Immunofluorescence - Anti-CRCP antibody [EPR9670(B)] (ab139264)

    Immunocytochemsitry/Immunofluorescence analysis of LnCap cells labelling CRCP (red) with purified ab139264 at 1/250. Cells were fixed with 4% paraformaldehyde. An Alexa Fluor® 555-conjugated goat anti-rabbit IgG (1/200) was used as the secondary antibody. Counterstained with DAPI (blue).

  • Immunocytochemistry/ Immunofluorescence - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Immunocytochemistry/ Immunofluorescence - Anti-CRCP antibody [EPR9670(B)] (ab139264)

    Immunocytochemistry/Immunofluorescence analysis of HeLa cells labelling CRCP with unpurified ab139264 at 1/100.

  • Immunoprecipitation - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Immunoprecipitation - Anti-CRCP antibody [EPR9670(B)] (ab139264)

    ab139264 (unpurified) at 1/50 immunoprecipitating CRCP in human prostate cancer tissue lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).

    Blocking buffer and concentration: 5% NFDM/TBST.

    Diluting buffer and concentration: 5% NFDM /TBST.

  • Immunoprecipitation - Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Immunoprecipitation - Anti-CRCP antibody [EPR9670(B)] (ab139264)

    ab139264 (purified) at 1/100 immunoprecipitating CRCP in human prostate cancer tissue lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).

    Blocking buffer and concentration: 5% NFDM/TBST.

    Diluting buffer and concentration: 5% NFDM /TBST.

  • Anti-CRCP antibody [EPR9670(B)] (ab139264)
    Anti-CRCP antibody [EPR9670(B)] (ab139264)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

© 2021 Astana Biomed Group LLP. All rights reserved.